Literature DB >> 25176981

Treating advanced cardiac damage in light chain amyloidosis: still an unmet need.

Giampaolo Merlini1, Giovanni Palladini2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25176981      PMCID： PMC4562528          DOI： 10.3324/haematol.2014.113464

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  20 in total

1.  Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL.

Authors:  Giovanni Palladini; Francesca Lavatelli; Paola Russo; Stefano Perlini; Vittorio Perfetti; Tiziana Bosoni; Laura Obici; Arthur R Bradwell; GianVico Melzi D'Eril; Roberto Fogari; Remigio Moratti; Giampaolo Merlini
Journal:  Blood       Date:  2006-01-24       Impact factor: 22.113

2.  A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis.

Authors:  Ashutosh D Wechalekar; Stefan O Schonland; Efstathios Kastritis; Julian D Gillmore; Meletios A Dimopoulos; Thirusha Lane; Andrea Foli; Darren Foard; Paolo Milani; Lisa Rannigan; Ute Hegenbart; Philip N Hawkins; Giampaolo Merlini; Giovanni Palladini
Journal:  Blood       Date:  2013-03-11       Impact factor: 22.113

3.  Mechanical strain activates BNP gene transcription through a p38/NF-kappaB-dependent mechanism.

Authors:  F Liang; D G Gardner
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

4.  Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway.

Authors:  Jianru Shi; Jian Guan; Bingbing Jiang; Daniel A Brenner; Federica Del Monte; Jennifer E Ward; Lawreen H Connors; Douglas B Sawyer; Marc J Semigran; Thomas E Macgillivray; David C Seldin; Rodney Falk; Ronglih Liao
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-11       Impact factor: 11.205

5.  Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis.

Authors:  Giovanni Palladini; Carlo Campana; Catherine Klersy; Alessandra Balduini; Giovanbattista Vadacca; Vittorio Perfetti; Stefano Perlini; Laura Obici; Edoardo Ascari; Gianvico Melzi d'Eril; Remigio Moratti; Giampaolo Merlini
Journal:  Circulation       Date:  2003-04-28       Impact factor: 29.690

6.  Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis.

Authors:  Jennifer Ellis Ward; Ruiyi Ren; Gianluca Toraldo; Pam Soohoo; Jian Guan; Carl O'Hara; Ravi Jasuja; Vickery Trinkaus-Randall; Ronglih Liao; Lawreen H Connors; David C Seldin
Journal:  Blood       Date:  2011-10-12       Impact factor: 22.113

Review 7.  Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.

Authors:  R A Kyle; B G M Durie; S V Rajkumar; O Landgren; J Blade; G Merlini; N Kröger; H Einsele; D H Vesole; M Dimopoulos; J San Miguel; H Avet-Loiseau; R Hajek; W M Chen; K C Anderson; H Ludwig; P Sonneveld; S Pavlovsky; A Palumbo; P G Richardson; B Barlogie; P Greipp; R Vescio; I Turesson; J Westin; M Boccadoro
Journal:  Leukemia       Date:  2010-04-22       Impact factor: 11.528

8.  Antibodies to human serum amyloid P component eliminate visceral amyloid deposits.

Authors:  Karl Bodin; Stephan Ellmerich; Melvyn C Kahan; Glenys A Tennent; Andrzej Loesch; Janet A Gilbertson; Winston L Hutchinson; Palma P Mangione; J Ruth Gallimore; David J Millar; Shane Minogue; Amar P Dhillon; Graham W Taylor; Arthur R Bradwell; Aviva Petrie; Julian D Gillmore; Vittorio Bellotti; Marina Botto; Philip N Hawkins; Mark B Pepys
Journal:  Nature       Date:  2010-10-20       Impact factor: 49.962

9.  Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types.

Authors:  Claudio Rapezzi; Giampaolo Merlini; Candida C Quarta; Letizia Riva; Simone Longhi; Ornella Leone; Fabrizio Salvi; Paolo Ciliberti; Francesca Pastorelli; Elena Biagini; Fabio Coccolo; Robin M T Cooke; Letizia Bacchi-Reggiani; Diego Sangiorgi; Alessandra Ferlini; Michele Cavo; Elena Zamagni; Maria Luisa Fonte; Giovanni Palladini; Francesco Salinaro; Francesco Musca; Laura Obici; Angelo Branzi; Stefano Perlini
Journal:  Circulation       Date:  2009-09-14       Impact factor: 29.690

10.  AL amyloid imaging and therapy with a monoclonal antibody to a cryptic epitope on amyloid fibrils.

Authors:  Jonathan S Wall; Stephen J Kennel; Angela Williams; Tina Richey; Alan Stuckey; Ying Huang; Sallie Macy; Robert Donnell; Robin Barbour; Peter Seubert; Dale Schenk
Journal:  PLoS One       Date:  2012-12-26       Impact factor: 3.240
View more
  3 in total

1.  Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study.

Authors:  Anita D'Souza; Angela Dispenzieri; Baldeep Wirk; Mei-Jie Zhang; Jiaxing Huang; Morie A Gertz; Robert A Kyle; Shaji Kumar; Raymond L Comenzo; Robert Peter Gale; Hillard M Lazarus; Bipin N Savani; Robert F Cornell; Brendan M Weiss; Dan T Vogl; César O Freytes; Emma C Scott; Heather J Landau; Jan S Moreb; Luciano J Costa; Muthalagu Ramanathan; Natalie S Callander; Rammurti T Kamble; Richard F Olsson; Siddhartha Ganguly; Taiga Nishihori; Tamila L Kindwall-Keller; William A Wood; Tomer M Mark; Parameswaran Hari
Journal:  J Clin Oncol       Date:  2015-09-14       Impact factor: 44.544

2.  Racial disparities in patients diagnosed with light chain (AL) amyloidosis.

Authors:  Anita D'Souza; Liliana Pezzin; Purushottam Laud; Ashima Singh
Journal:  Blood Cancer J       Date:  2021-04-10       Impact factor: 11.037

3.  [Treatment of systemic AL amyloidosis: about 25 cases].

Authors:  Hicham Eddou; Ali Zinebi; Hicham El Maaroufi; Mohammed Karim Moudden; Kamal Doghmi; Mohammed Mikdame; Mohammed El Baaj
Journal:  Pan Afr Med J       Date:  2017-10-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.